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Edited by Beat ImhofAbstract We previously showed that endothelin-1 (ET-1) stim-
ulates the synthesis of interleukin-6 (IL-6), a potent bone resorp-
tive agent, in osteoblast-like MC3T3-E1 cells, and that protein
kinase C (PKC)-dependent p44/p42 mitogen-activated protein
(MAP) kinase plays a part in the IL-6 synthesis. In the present
study, we investigated the eﬀect of ()-epigallocatechin gallate
(EGCG), one of the major ﬂavonoids containing in green tea,
on ET-1-induced IL-6 synthesis in osteoblasts and the underlying
mechanism. EGCG signiﬁcantly reduced the synthesis of IL-6
stimulated by ET-1 in MC3T3-E1 cells as well primary cultured
mouse osteoblasts. SB203580, a speciﬁc inhibitor of p38 MAP
kinase, but not SP600125, a speciﬁc SAPK/JNK inhibitor, sup-
pressed ET-1-stimulated IL-6 synthesis. ET-1-induced phosphor-
ylation of p38 MAP kinase was not aﬀected by EGCG. On the
other hand, EGCG suppressed the phosphorylation of p44/p42
MAP kinase induced by ET-1. Both the IL-6 synthesis and the
phosphorylation of p44/p42 MAP kinase stimulated by 12-O-tet-
radecanoylphorbol 13-acetate (TPA), a direct activator of PKC,
were markedly suppressed by EGCG. The phosphorylation of
MEK1/2 and Raf-1 induced by ET-1 or TPA were also inhibited
by EGCG. These results strongly suggest that EGCG inhibits
ET-1-stimulated synthesis of IL-6 via suppression of p44/p42
MAP kinase pathway in osteoblasts, and the inhibitory eﬀect
is exerted at a point between PKC and Raf-1 in the ET-1 signal-
ing cascade.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Interleukin-6 (IL-6) is a pleiotropic cytokine that has impor-
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doi:10.1016/j.febslet.2007.02.052promoting B cell diﬀerentiation, T cell activation and inducing
acute phase proteins [1–4]. The bone metabolism is regulated
by two functional cells, osteoblasts and osteoclasts, responsible
for bone formation and bone resorption, respectively [5]. The
formation of bone structures and bone remodeling results from
the coupling process, bone resorption by activated osteoclasts
with subsequent deposition of new matrix by osteoblasts. It is
well recognized that IL-6 is one of the most potent osteoclas-
togenic factors in the bone metabolism [3,4]. Bone resorption
is mediated by the increased local production of inﬂammatory
cytokines such as tumor necrosis factor-a and IL-1. In osteo-
blasts [6–8], bone resorptive agents such as tumor necrosis fac-
tor-a and IL-1 have been reported to stimulate the synthesis of
IL-6. As for the bone metabolism, IL-6 has been shown to
stimulate bone resorption and induce osteoclast formation
[3,4,6,9]. Therefore, accumulating evidence indicates that IL-
6 secreted from osteoblasts plays a key role as a downstream
eﬀector of bone resorptive agents. In previous studies [10,11],
we have shown that endothelin-1 (ET-1) induces the activation
of p44/p42 mitogen-activated protein (MAP) kinase, a member
of the MAP kinase superfamily [12], via protein kinase C
(PKC), resulting in the IL-6 synthesis in osteoblast-like
MC3T3-E1 cells. However, the mechanism of ET-1 behind
the IL-6 synthesis in osteoblasts has not yet been precisely clari-
ﬁed.
It is well known that compounds in foods such as vegetables
and fruits have beneﬁcial properties on human beings. Among
them, it has been reported that ﬂavonoids possess antioxida-
tive, antibacterial and antitumor eﬀects [13,14]. Catechins are
one of the major ﬂavonoids, which are present in various spe-
cies of plants such as green tea [14]. In bone metabolism, cat-
echin has been shown to suppress bone resorption [15]. As for
osteoblasts, it has been shown that catechin stimulates alkaline
phosphatase activity, a mature osteoblast phenotype [5], and
reduces apoptosis in osteoblast-like MC3T3-E1 cells [16].
However, the precise mechanism of catechin in osteoblasts is
not fully known.
In the present study, we investigated whether ()-epigalloca-
techin gallate (EGCG), one of the major ﬂavonoids containing
in green tea, aﬀects the ET-1-stimulated IL-6 synthesis in
osteoblast-like MC3T3-E1 cells and the mechanism behind
it. We herein show that EGCG reduces the ET-1-stimulatedblished by Elsevier B.V. All rights reserved.
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way in these cells.2. Materials and methods
2.1. Materials
ET-1 and 12-O-tetradecanoylphorbol 13-acetate (TPA) were pur-
chased from Sigma Chemical Co. (St. Louis, MO). IL-6 ELISA kit
was purchased from R&D Systems, Inc. (Minneapolis, MN). EGCG,
SB203580 and SP600125 were obtained from Calbiochem-Novabio-
chem Co. (La Jolla, CA). Phospho-speciﬁc p38 MAP kinase antibod-
ies, p38 MAP kinase antibodies, phospho-speciﬁc p44/p42MAP kinase
antibodies, p44/p42 MAP kinase antibodies, phospho-speciﬁc MEK1/2
antibodies, MEK1/2 antibodies, phospho-speciﬁc Raf-1 antibodies and
b-actin antibodies were purchased from Cell Signaling Technology
(Beverly, MA). ECL Western blotting detection system was purchased
from Amersham Japan (Tokyo, Japan). Other materials and chemicals
were obtained from commercial sources. SB203580 and SP600125 were
dissolved in dimethyl sulfoxide. The maximum concentration of di-
methyl sulfoxide was 0.1%, which did not aﬀect either the assay for
IL-6 activity or the Western blotting analysis.Table 1
Eﬀects of EGCG, SB203580 or SP600125 on the ET-1-stimulated IL-6
synthesis in MC3T3-E1 cells2.2. Cell culture
The cloned osteoblast-like MC3T3-E1 cells, which have been derived
from newborn mouse calvaria [17], were maintained as previously de-
scribed [18]. Brieﬂy, the cells were cultured in a-minimum essential
medium (a-MEM) containing 10% fetal calf serum (FCS) at 37 C in
a humidiﬁed atmosphere of 5% CO2/95% air. The cells were seeded
into 35-mm diameter dishes (5 · 104/dish) or 90-mm diameter dishes
(5 · 105/dish) in a-MEM containing 10% FCS. After 5 days, the med-
ium was exchanged for a-MEM containing 0.3% FCS. The cells were
used for experiments after 48 h.
Primary cultured mouse osteoblasts were obtained from neonatal
balb/c mouse by sequential collagenase digestions as previously de-
scribed [19]. In brief, the calvarias of the neonatal mice were aseptically
dissected from neonatal mice. The calvarias which were divided into
small pieces were sequentially digested with 5 ml of PBS containing
0.1% collagenase (Sigma, MO) for 5 min at 37 C. The cells isolated
in fractions 2–6 were seeded into 90-mm diameter dishes in a-MEM
containing 10% FCS at 37 C in a humidiﬁed atmosphere of 5%
CO2/95% air. The medium was exchanged at every 3 days. After reach-
ing conﬂuence, the cells were subcultured. After trypsinization using
trypsin-EDTA (0.05%/0.53 mM), the cells were rinsed three times in
10 ml of PBS. The cells (1 · 105) were seeded into 35-mm diameter
dishes in 2 ml of a-MEM containing 10% FCS. After reaching conﬂu-
ency, the medium was exchanged for a-MEM containing 0.3% FCS.
The cells were used for experiments after 48 h. We conﬁrmed that
the cultured cells possessed the high alkaline phosphatase activity, a
mature osteoblasts phenotype [20].EGCG or inhibitor ET-1 IL-6 (pg/ml)
Vehicle  16 ± 5
Vehicle + 468 ± 38*
EGCG (1 lM)  15 ± 10
EGCG (1 lM) + 419 ± 35
EGCG (10 lM)  17 ± 8
EGCG (10 lM) + 414 ± 302.3. Assay for IL-6
The cultured cells were stimulated by ET-1 in 1 ml of a-MEM con-
taining 0.3% FCS, and then incubated for the indicated periods. The
conditioned medium was collected, and IL-6 in the medium was then
measured by an IL-6 ELISA kit. When indicated, the cells were pre-
treated with EGCG, SB203580 or SP600125 for 60 min.EGCG (50 lM)  15 ± 10
EGCG (50 lM) + 347 ± 28**
EGCG (100 lM)  23 ± 8
EGCG (100 lM) + 69 ± 12**
SB203580  10 ± 7
SB203580 + 85 ± 12**
SP600125  15 ± 10
SP600125 + 456 ± 29
The cultured cells were pretreated with various doses of EGCG, 10 lM
SB203580, 10 lM SP600125 or vehicle for 60 min, and then stimulated
by 0.1 lM ET-1 or vehicle for 24 h. Each value represents the means ±
S.E.M. of triplicate determinations. Similar results were obtained with
two additional and diﬀerent cell preparations.
*P < 0.05, compared to the control value.
**P < 0.05, compared to the value of ET-1 alone.2.4. Analysis of Western blotting
The cultured cells were stimulated by ET-1 in a-MEM containing
0.3% FCS for the indicated periods. The cells were washed twice with
phosphate-buﬀered saline and then lysed, homogenized and sonicated
in a lysis buﬀer containing 62.5 mM Tris/HCl, pH 6.8, 2% sodium
dodecyl sulfate (SDS), 50 mM dithiothreitol and 10% glycerol. The
cytosolic fraction was collected as a supernatant after centrifugation
at 125000 · g for 10 min at 4 C. SDS–polyacrylamide gel electropho-
resis (PAGE) was performed by Laemmli [21] in 10% polyacrylamide
gel. A Western blotting analysis was performed as described previously
[22] by using phospho-speciﬁc p38 MAP kinase antibodies, p38 MAP
kinase antibodies, phospho-speciﬁc p44/p42 MAP kinase or p44/p42
MAP kinase with peroxidase-labeled antibodies raised in goat against
rabbit IgG being used as second antibodies. The peroxidase activity onPVDG membrane was visualized on X-ray ﬁlm by means of the ECL
Western blotting detection system. When indicated, the cells were pre-
treated with various doses of EGCG for 60 min.
2.5. Determinations
The absorbance of enzyme immunoassay samples was measured at
450 nm with EL 340 Bio Kinetic Reader (Bio-Tek Instruments, Inc.,
Winooski, VT). A densitometric analysis was performed using the
Molecular Analyst/Macintosh software program (Bio-Rad Laborato-
ries, Hercules, CA).
2.6. Statistical analysis
The data were analyzed by ANOVA followed by the Bonferroni
method for multiple comparisons between pairs, and a P < 0.05 was
considered signiﬁcant. All data are presented as the means ± S.E.M.
of triplicate determinations. Each experiment was repeated three times
with similar results.3. Results
3.1. Eﬀects of EGCG on the ET-1-stimulated IL-6 synthesis in
MC3T3-E1 cells and primary cultured mouse osteoblasts
We have previously demonstrated that ET-1 stimulates IL-6
synthesis in osteoblast-like MC3T3-E1 cells [10]. We ﬁrst
examined the eﬀect of EGCG on the ET-1-stimulated IL-6 syn-
thesis. EGCG, which alone had little eﬀect on the IL-6 levels,
reduced the ET-1-stimulated synthesis of IL-6 in a dose-depen-
dent manner in the range between 1 and 100 lM (Table 1). In
addition, we also examined the eﬀect of EGCG in primary cul-
tured mouse osteoblasts, and found that EGCG (30 lM) sig-
niﬁcantly reduced the IL-6 synthesis induced by ET-1 (Table
2). EGCG (30 lM) caused about a 55% reduction in the ET-
1-eﬀect.
3.2. Eﬀects of SB203580 or SP600125 on the ET-1-stimulated
IL-6 synthesis in MC3T3-E1 cells
In our previous study [11], we reported that p44/p42 MAP
kinase plays a part in the ET-1-stimulated IL-6 synthesis in
MC3T3-E1 cells. Among the MAP kinase superfamily, p38
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Fig. 1. Eﬀect of EGCG on the phosphorylation of p38 MAP kinase
induced by ET-1 in MC3T3-E1 cells. The cultured cells were pretreated
with the indicated doses of EGCG or vehicle for 60 min, and then
stimulated by 3 nM ET-1 or vehicle for 20 min. The extracts of cells
were subjected to SDS–PAGE with a subsequent Western blotting
analysis with antibodies against phospho-speciﬁc p38 MAP kinase or
p38 MAP kinase. The histogram shows quantitative representations of
the levels of ET-1-induced phosphorylation obtained from a laser
Table 2
Eﬀects of EGCG on the ET-1-stimulated IL-6 synthesis in primary
cultured mouse osteoblasts
EGCG ET-1 IL-6 (pg/ml)
  248 ± 39
 + 354 ± 26*
+  216 ± 8
+ + 263 ± 26**
The cultured cells were pretreated with 30 lM EGCG or vehicle for
60 min, and then stimulated by 0.1 lM ET-1 or vehicle for 24 h. Each
value represents the means ± S.E.M. of triplicate determinations.
Similar results were obtained with two additional and diﬀerent cell
preparations.
*P < 0.05, compared to the control value.
**P < 0.05, compared to the value of ET-1 alone.
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N-terminal kinase (JNK) in addition to p44/p42 MAP kinase,
which together play a crucial role as intracellular components
to transduce the various signals of agonists [12]. We have pre-
viously shown that ET-1 also activates p38 MAP kinase and
SAPK/JNK [23,24]. In order to clarify the involvement of
the MAP kinases in the ET-1-stimulated IL-6 synthesis in these
cells, we examined the eﬀect of SB203580, a speciﬁc inhibitor
of p38 MAP kinase [25], or SP600125, a speciﬁc SAPK/JNK
inhibitor [26], on the IL-6 synthesis. SB203580, which by itself
had little eﬀect on the IL-6 levels, signiﬁcantly suppressed the
ET-1-stimulated synthesis of IL-6 (Table 1). On the other
hand, SP600125 hardly aﬀected the IL-6 synthesis induced
by ET-1 (Table 1).densitometric analysis of three independent experiments. Each value
represents the means ± S.E.M. of triplicate determinations. Similar
results were obtained with two additional and diﬀerent cell prepara-
tions.3.3. Eﬀect of EGCG on the phosphorylation of p38 MAP kinase
by ET-1 in MC3T3-E1 cells
In order to clarify whether p38 MAP kinase is involved in
EGCG-eﬀect on the ET-1-stimulated IL-6 synthesis in
MC3T3-E1 cells, we examined the eﬀect of EGCG on the
ET-1-induced phosphorylation of p38 MAP kinase. However,
EGCG had little eﬀect on the ET-1-induced phosphorylation
of p38 MAP kinase (Fig. 1).3.4. Eﬀect of EGCG on the phosphorylation of p44/p42 MAP
kinase induced by ET-1 in MC3T3-E1 cells
In order to investigate whether EGCG-eﬀect on the ET-1-
stimulated IL-6 synthesis is mediated through p44/p42 MAP
kinase activation in MC3T3-E1 cells, we next examined the
eﬀect of EGCG on the ET-1-induced phosphorylation of
p44/p42 MAP kinase. EGCG markedly attenuated the ET-1-
induced phosphorylation of p44/p42 MAP kinase (Fig. 2).
According to the densitometric analysis, EGCG (100 lM)
caused about 80% reduction in the ET-1-eﬀect.
3.5. Eﬀects of EGCG on the TPA-stimulated IL-6 synthesis in
MC3T3-E1 cells
We previously reported that PKC functions at a point up-
stream from p44/p42 MAP kinase in the ET-1-stimulated IL-
6 synthesis in osteoblast-like MC3T3-E1 cells [11]. We next
examined the eﬀect of EGCG on the IL-6 synthesis stimulated
by TPA, a direct activator of PKC [27]. In our previous study
[28], we found that TPA alone stimulates IL-6 synthesis in
MC3T3-E1 cells. EGCG, which by itself had little eﬀect on
the IL-6 levels, signiﬁcantly reduced the TPA-stimulated syn-thesis of IL-6 (Table 3). EGCG (100 lM) caused about an
80% reduction in the TPA-eﬀect.
3.6. Eﬀect of EGCG on the phosphorylation of p44/p42 MAP
kinase induced by TPA in MC3T3-E1 cells
In order to investigate whether EGCC-eﬀect on the TPA-
stimulated IL-6 synthesis is mediated through inhibition of
p44/p42 MAP kinase activation in MC3T3-E1 cells, we next
examined the eﬀect of EGCC on the TPA-induced phosphor-
ylation of p44/p42 MAP kinase. We previously found that
TPA induces the phosphorylation of p44/p42 MAP kinase in
these cells [29]. EGCC markedly suppressed the TPA-induced
phosphorylation of p44/p42 MAP kinase (Fig. 3).
3.7. Eﬀects of EGCG on the phosphorylation of MEK1/2 and
Raf-1 induced by ET-1 or TPA in MC3T3-E1 cells
It is well known that p44/p42 MAP kinase is activated by an
upstream kinase, MEK1/2, which is activated by Raf-1 [12]. To
clarify the exact mechanism of EGCG behind the IL-6 synthe-
sis, we further examined the eﬀects of EGCG on the phosphor-
ylation of MEK1/2 and Raf-1 induced by ET-1 or TPA in
MC3T3-E1 cells. The levels of ET-1 or TPA-induced phos-
phorylation of MEK1/2 were reduced by EGCG (data not
shown). EGCG suppressed the levels of both ET-1- and
TPA-induced the phosphorylation of Raf-1 (Fig. 4).
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Fig. 2. Eﬀect of EGCG on the phosphorylation of p44/p42 MAP
kinase induced by ET-1 in MC3T3-E1 cells. The cultured cells were
pretreated with the indicated doses of EGCG or vehicle for 60 min,
and then stimulated by 3 nM ET-1 or vehicle for 5 min. The extracts of
the cells were subjected to SDS–PAGE with a subsequent Western
blotting analysis with antibodies against phospho-speciﬁc p44/p42
MAP kinase or p44/p42 MAP kinase. The histogram shows quanti-
tative representations of the levels of ET-1-induced phosphorylation
obtained from a laser densitometric analysis of three independent
experiments. Each value represents the means ± S.E.M. of triplicate
determinations. Similar results were obtained with two additional and
diﬀerent cell preparations. *P < 0.05, compared to the value of ET-1
alone.
Table 3
Eﬀect of EGCG on the TPA-stimulated IL-6 synthesis in MC3T3-E1
cells
EGCG TPA IL-6 (pg/ml)
  19 ± 7
 + 415 ± 31*
+  29 ± 10
+ + 98 ± 17**
The cultured cells were pretreated with 100 lM EGCG or vehicle for
60 min, and then stimulated by 0.1 lM TPA or vehicle for 24 h. Each
value represents the means ± S.E.M. of triplicate determinations.
Similar results were obtained with two additional and diﬀerent cell
preparations.
*P < 0.05, compared to the control value.
**P < 0.05, compared to the value of TPA alone.
Lane 1 2 3 4
EGCG
TPA
Phospho-p44/p42
p44/p42
0
10
20
30
1 2 3 4
esaerc
ni
 dl
oF
Lane
*
Fig. 3. Eﬀect of EGCG on the phosphorylation of p44/p42 MAP
kinase induced by TPA in MC3T3-E1 cells. The cultured cells were
pretreated with 100 lM EGCG or vehicle for 60 min, and then
stimulated by 0.1 lM TPA or vehicle for 60 min. The extracts of cells
were subjected to SDS–PAGE with a subsequent Western blotting
analysis with antibodies against phospho-speciﬁc p44/p42 MAP kinase
or p44/p42 MAP kinase. The histogram shows quantitative represen-
tations of the levels of TPA-induced phosphorylation obtained from a
laser densitometric analysis of three independent experiments. Each
value represents the means ± S.E.M. of triplicate determinations.
Similar results were obtained with two additional and diﬀerent cell
preparations. *P < 0.05, compared to the value of TPA alone.
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In the present study, we showed that EGCG, which by itself
had little eﬀect on the levels of IL-6, signiﬁcantly reduced the
ET-1-stimulated IL-6 synthesis in osteoblast-like MC3T3-E1
cells. We found that EGCG reduced the IL-6 synthesis induced
by ET-1 also in primary cultured mouse osteoblasts. It is likely
that the inhibitory eﬀect of EGCG on the IL-6 synthesis in-
duced by ET-1 is not speciﬁc in a clonal osteoblast-likeMC3T3-E1 cells but it is common in osteoblasts. We next
investigated the mechanism of EGCG underlying the suppres-
sive eﬀect on the IL-6 synthesis. It is generally known that the
MAP kinase superfamily plays a pivotal role in cellular func-
tions including proliferation, diﬀerentiation, and cell death in
a variety of cells [12]. Three major MAP kinase, p44/p42
MAP kinase, p38 MAP kinase, and SAPK/JNK are known
as central elements used by mammalian cells to transduce the
diverse messages [12]. We have previously reported that ET-
1-activated p44/p42 MAP kinase acts as a positive regulator
in ET-1-induced IL-6 synthesis in osteoblast-like MC3T3-E1
cells [11]. In addition, we demonstrated that p38 MAP kinase
and SAPK/JNK are activated by ET-1 in these cells [23,24]. In
the present study, we showed that SB203580 [25], markedly
suppressed the ET-1-induced IL-6 synthesis while SP600125
[26], failed to aﬀect the IL-6 synthesis. We previously showed
that ET-1-induced both synthesis of vascular endothelial
growth factor and phosphorylation of SAPK/JNK are signiﬁ-
cantly suppressed by 10 lM SP600125 in MC3T3-E1 cells [24].
It thus seems unlikely that SAPK/JNK is involved in the ET-1-
induced IL-6 synthesis in osteoblast-like MC3T3-E1 cells.
Based on our results, it is probable that ET-1 stimulates the
synthesis of IL-6 via p38 MAP kinase in addition to p44/p42
MAP kinase in osteoblast-like MC3T3-E1 cells.
We further investigated the involvement of p38 MAP kinase
and p44/p42 MAP kinase in the inhibitory eﬀect of EGCG on
the IL-6 synthesis. EGCG attenuated the ET-1-induced phos-
phorylation of p44/p42 MAP kinase without aﬀecting the p38
MAP kinase phosphorylation. Therefore, our ﬁndings strongly
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Fig. 4. Eﬀects of EGCG on the phosphorylation of Raf-1 induced by
ET-1 or TPA in MC3T3-E1 cells. The cultured cells were pretreated
with 100 lM EGCG or vehicle for 60 min, and then stimulated by
0.1 lM ET-1 (A), 0.1 lM TPA (B) or vehicle for 60 min. The extracts
of cells were subjected to SDS–PAGE with a subsequent Western
blotting analysis with antibodies against phospho-speciﬁc Raf-1 or b-
actin. The histogram shows quantitative representations of the levels of
ET-1- (A) or TPA-induced phosphorylation (B) obtained from a laser
densitometric analysis of three independent experiments. Each value
represents the means ± S.E.M. of triplicate determinations. Similar
results were obtained with two additional and diﬀerent cell prepara-
tions. *P < 0.05, compared to the value of ET-1 (A) or TPA (B) alone.
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sis via the down-regulating p44/p42 MAP kinase pathway in
osteoblast-like MC3T3-E1 cells. In our previous studies
[10,11], we demonstrated that p44/p42 MAP kinase acts at a
point downstream of PKC in ET-1-stimulated IL-6 synthesis
in MC3T3-E1 cells. To clarify whether the eﬀect of catechinis exerted at a point downstream of PKC or not, we addition-
ally examined the eﬀect of EGCG on the IL-6 synthesis by
TPA [27]. We have found that TPA alone stimulates IL-6 syn-
thesis in MC3T3-E1 cells [28]. We herein presented that EGCG
reduced the TPA-stimulated IL-6 synthesis as well as the TPA-
induced phosphorylation of p44/p42 MAP kinase in these cells,
suggesting that the eﬀect of EGCG is exerted at a point up-
stream of p44/p42 MAP kinase. Furthermore, we found that
EGCG actually suppressed the levels of both ET-1- and
TPA-induced phosphorylation of MEK1/2 and Raf-1. Taking
our ﬁndings into account as a whole, it is most likely that
EGCG down-regulates ET-1-stimulated IL-6 synthesis in oste-
oblasts, and that the eﬀect is exerted at a point between PKC
and Raf-1. Further investigations are necessary to clarify the
precise mechanism of catechin underlying the down-regulation
of IL-6 synthesis in osteoblasts.
IL-6 is well recognized to be a potent bone resorptive agent
and induces osteoclast formation [4,6]. On the other hand, cat-
echin reportedly has an inhibitory eﬀect on bone resorption
[15]. In addition, it has recently been shown that catechin
increases cell viability and alkaline phosphatase activity, a
marker of mature osteoblast phenotype [5], in osteoblast-like
MC3T3-E1 cells and apoptosis of these cells is suppressed by
catechin [16]. Taking our results into account, it is probable
that catechin-induced suppression of p44/p42 MAP kinase
activation plays an eﬀect against bone resorption via down-
regulating IL-6 synthesis in osteoblasts. Our present data
therefore provide new insight into the pharmacological eﬀects
of catechin action on bone cells. Further investigations are
required to elucidate the exact role of catechin in the bone
metabolism.
In conclusion, these results strongly suggest that catechin
inhibits the ET-1-stimulated synthesis of IL-6 via suppression
of p44/p42 MAP kinase pathway in osteoblasts, and this eﬀect
is exerted at a point between PKC and Raf-1 in the ET-1 sig-
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